|27.45|| 0.00 / 0.00%|
Radius Health, Inc. engages in the discovery and development of therapeutics for the treatment of osteoporosis, oncology, and endocrine diseases. The firm's lead product, abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
|Jesper Høiland||President, Chief Executive Officer& Director|
|Jose Carmona||CFO, Treasurer, Principal Accounting Officer & SVP|
|Gary Hattersley||Chief Scientific Officer|
|Lorraine A. Fitzpatrick||Chief Medical Officer|
|Brent Hatzis-Schoch||Senior Vice President & General Counsel|